SG Americas Securities
AVBP icon

SG Americas Securities’s ArriVent BioPharma AVBP Stock Holding History

SG Americas Securities’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Sell
48,716
-2,721
-5% -$61.5K ﹤0.01% 1691
2025
Q4 		$1.03M Buy
51,437
+14,495
+39% +$302K ﹤0.01% 1983
2025
Q3 		$682K Buy
36,942
+9,469
+34% +$186K ﹤0.01% 1835
2025
Q2 		$598K Buy
27,473
+4,793
+21% +$99.5K ﹤0.01% 1541
2025
Q1 		$419K Buy
22,680
+10,873
+92% +$266K ﹤0.01% 1924
2024
Q4 		$315K Sell
11,807
-120
-1% -$3.44K ﹤0.01% 1750
2024
Q3 		$280K Buy
+11,927
New +$271K ﹤0.01% 2217

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SG Americas Securities's AVBP Position: Q1 2026 in Review

SG Americas Securities reduced its ArriVent BioPharma (AVBP) stake by 5.3% in Q1 2026, selling an estimated $61.5K and leaving 48,716 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1691.

SG Americas Securities first reported a position in AVBP in Q3 2024 and has held it in 7 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • SG Americas Securities held 48,716 shares of ArriVent BioPharma worth $1.12M as of Q1 2026.
  • SG Americas Securities sold 2,721 ArriVent BioPharma shares in Q1 2026, an estimated $61.5K.
  • ArriVent BioPharma made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1691 holding.
  • SG Americas Securities first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 7 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.